Literature DB >> 26236659

Therapeutic Efficacy of Orally Delivered Doxorubicin Nanoparticles in Rat Tongue Cancer Induced by 4-Nitroquinoline 1-Oxide.

Monir Moradzadeh Khiavi1, Ahamd Rostami2, Hamed Hamishekar3, Mehran Mesgari Abassi3, Amirala Aghbali2, Roya Salehi3, Bita Abdollahi3, Soheila Fotoohi3, Mahmud Sina2.   

Abstract

PURPOSE: Oral cancer is one of the most significant cancers in the world, and squamous cell carcinoma makes up about 94% of oral malignancies. The aim of the present study was to compare the efficacy of doxorubicin plus methotrexate - loaded nanoparticles on tongue squamous cell carcinoma induced by 4NQO and compare it with the commercial doxorubicin and methotrexate delivered orally on seventy SD male rats.
METHODS: 70 rats were divided into five groups. During the study, the animals were weighed by a digital scale once a week. Number of mortalities was recorded in the data collection forms. At the end of the treatment, biopsy samples were taken from rat tongues in order to evaluate the severity of dysplasia and the extent of cell proliferation. The results were analyzed using ANOVA, descriptive statistics and chi-square test.
RESULTS: No statistically significant difference was found in the mean weight of five groups (p>0.05). No significant relationship was found between groups and mortality rate (P = 0. 39). In addition, there was a significant relationship between groups and the degree of dysplasia (P <0.001). The statistical analysis showed a significant relationship between groups and the rate of cell proliferation (p <0.001).
CONCLUSION: The results of the present study showed that the use of doxorubicin plus methotrexate - loaded nanoparticles orally had more therapeutic effects than commercial doxorubicin plus methotrexate.

Entities:  

Keywords:  4-NQO; Doxorubicin; Nanoparticles; Oral; Rats; Squamous cell carcinoma

Year:  2015        PMID: 26236659      PMCID: PMC4517077          DOI: 10.15171/apb.2015.029

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  26 in total

1.  4NQO oral carcinogenesis: animal models, molecular markers and future expectations.

Authors:  Marilena Vered; Noam Yarom; Dan Dayan
Journal:  Oral Oncol       Date:  2004-11-23       Impact factor: 5.337

2.  Systemic chemotherapy for cancer: from weapon to treatment.

Authors:  Heikki Joensuu
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

3.  Nanoparticles: Emerging carriers for drug delivery.

Authors:  Sagar R Mudshinge; Amol B Deore; Sachin Patil; Chetan M Bhalgat
Journal:  Saudi Pharm J       Date:  2011-04-21       Impact factor: 4.330

4.  Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide.

Authors:  H Shiotani; A Denda; K Yamamoto; W Kitayama; T Endoh; Y Sasaki; N Tsutsumi; M Sugimura; Y Konishi
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

5.  Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.

Authors:  Derajram M Benival; Padma V Devarajan
Journal:  Int J Pharm       Date:  2011-12-02       Impact factor: 5.875

6.  Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death.

Authors:  Puay-Hoon Tan; Boon-Huat Bay; George Yip; Sathiyamoorthy Selvarajan; Patrick Tan; Jeanie Wu; Chee-How Lee; Kuo-Bin Li
Journal:  Mod Pathol       Date:  2005-03       Impact factor: 7.842

7.  4-Nitroquinoline 1-oxide forms 8-hydroxydeoxyguanosine in human fibroblasts through reactive oxygen species.

Authors:  Yaeno Arima; Chikako Nishigori; Toru Takeuchi; Shigenori Oka; Kanehisa Morimoto; Atsushi Utani; Yoshiki Miyachi
Journal:  Toxicol Sci       Date:  2006-03-17       Impact factor: 4.849

8.  Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.

Authors:  Sebastian C J Steiniger; Jörg Kreuter; Alexander S Khalansky; Igor N Skidan; Alexey I Bobruskin; Zoya S Smirnova; Sergey E Severin; Reiner Uhl; Martin Kock; Kathrin D Geiger; Svetlana E Gelperina
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

9.  Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.

Authors:  Lara Milane; Zhenfeng Duan; Mansoor Amiji
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

10.  Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.

Authors:  Qun Wang; Yan-Jun Zhong; Jing-Ping Yuan; Li-Hua Shao; Jue Zhang; Li Tang; Shao-Ping Liu; Ya-Ping Hong; Raymond A Firestone; Yan Li
Journal:  J Transl Med       Date:  2013-08-21       Impact factor: 5.531

View more
  1 in total

1.  Assessment of the Blood Parameters, Cardiac and Liver Enzymes in Oral Squamous Cell Carcinoma Following Treated with Injectable Doxorubicin-Loaded Nano-Particles.

Authors:  Monir Moradzadeh Khiavi; Enayat Anvari; Hamed Hamishehkar; Khadijeh Abdal
Journal:  Asian Pac J Cancer Prev       Date:  2019-07-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.